The 2025 Milliman Medical Index confirms what many employers are seeing firsthand: prescription drug costs are rising faster than any other health care expense, with a 9.7% increase over the past year. To help employers reclaim their drug spend, MedBen Rx offers a transparent approach that eliminates hidden costs by focusing on smarter pharmacy benefits.

Here are three key cost drivers this year â€“ and how MedBen Rx helps employers take back and maintain control:

medicine pills on counting tray

Specialty Drugs. Specialty medications now make up a growing share of pharmacy costs, with a 43% year-over-year increase reported in early 2025. MedBen Rx helps employers manage this trend through benefit preservation advocates who secure best-in-market pricing, and access to lower-cost alternatives like biosimilars.

Rebate Games. Traditional PBMs often keep a large share of manufacturer rebates, masking true drug costs… but MedBen Rx returns 100% of paid rebates to the plan. Additionally, we eliminate spread pricing and ensure full transparency â€“ so you see real savings with no hidden fees.

GLP-1 Medications. GLP-1 drugs (i.e., Ozempic and Wegovy) used to treat weight loss and diabetes rank among the top cost drivers in 2025. MedBen Rx offers a variety of options to manage these conditions, such as alternative therapies and coverage modifications.

In a market where pharmacy costs are increasingly complex, MedBen Rx brings clarity with a smarter, more transparent benefits model. To learn how we can help your organization reduce prescription drug costs, contact your broker or MedBen Marketing.